MX347175B - Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central. - Google Patents
Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.Info
- Publication number
- MX347175B MX347175B MX2011013991A MX2011013991A MX347175B MX 347175 B MX347175 B MX 347175B MX 2011013991 A MX2011013991 A MX 2011013991A MX 2011013991 A MX2011013991 A MX 2011013991A MX 347175 B MX347175 B MX 347175B
- Authority
- MX
- Mexico
- Prior art keywords
- autoantibodies
- nervous system
- central nervous
- monomers
- fragments
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 239000000178 monomer Substances 0.000 abstract 3
- 208000016192 Demyelinating disease Diseases 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 208000037955 postinfectious encephalomyelitis Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un anticuerpo IgM monoclonal humano, o una mezcla, monómero o fragmento activo del mismo, caracterizado porque se une de manera específica a estructuras y células del sistema nervioso central y que tiene: (i) un dominio variable de cadena pesada que comprende las secuencias de las regiones CDR1, CDR2, y CDR3 de CB2iE12, las cuales están contenidas en la SEQ ID NO: 27, y un dominio variable de cadena ligera que comprende las secuencias de las regiones CDR1, CDR2, y CDR3 de CB2iE12, las cuales están contenidas en la SEQ ID NO: 29; O (ii) un dominio variable de cadena pesad que comprende las secuencias de las regiones CDR1, CDR2, y CDR3 de CB2iE7, las cuales están contenidas en la SEQ ID NO: 31 y un dominio variable de cadena ligera que comprende las secuencias de las regiones DR1, CDR2, y CDR3 de CB2iE7, las cuales están contenidas en la SEQ ID NO: 33.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56835100A | 2000-05-10 | 2000-05-10 | |
| PCT/US2000/014902 WO2001085797A1 (en) | 2000-05-10 | 2000-05-30 | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX347175B true MX347175B (es) | 2017-04-17 |
Family
ID=24270921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011013991A MX347175B (es) | 2000-05-10 | 2000-05-30 | Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central. |
| MXPA02011163A MXPA02011163A (es) | 2000-05-10 | 2000-05-30 | Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02011163A MXPA02011163A (es) | 2000-05-10 | 2000-05-30 | Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central. |
Country Status (10)
| Country | Link |
|---|---|
| EP (3) | EP1294770B1 (es) |
| JP (2) | JP5670608B2 (es) |
| AT (1) | ATE536375T1 (es) |
| AU (2) | AU2000261978B2 (es) |
| BR (1) | BR0015875A (es) |
| CA (2) | CA2901451C (es) |
| ES (3) | ES2609494T3 (es) |
| IL (3) | IL152738A0 (es) |
| MX (2) | MX347175B (es) |
| WO (1) | WO2001085797A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| KR100657048B1 (ko) | 2001-12-04 | 2006-12-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트의 효능 측정 방법 |
| DK1485127T3 (da) | 2002-02-25 | 2011-10-03 | Elan Pharm Inc | Anvendelse af midler til behandling af inflammation |
| US20050069541A1 (en) * | 2003-01-24 | 2005-03-31 | Karlik Stephen J. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| WO2004110355A2 (en) | 2003-05-16 | 2004-12-23 | Mayo Foundation For Medical Education & Research | Compositions and methods including a recombinant human mab that promotes cns remyelination |
| DK1626992T3 (da) * | 2003-05-23 | 2010-09-20 | Crucell Holland Bv | Produktion af rekombinant IgM i PER.C6-celler |
| US20060099203A1 (en) | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
| US7501119B2 (en) | 2004-06-30 | 2009-03-10 | Mayo Foundation For Medical Education And Research | Methods and molecules for modulating an immune response |
| NZ579594A (en) | 2007-03-12 | 2012-03-30 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
| CN111253484A (zh) * | 2007-06-25 | 2020-06-09 | 艾斯巴技术-诺华有限责任公司 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
| US9908945B2 (en) | 2007-06-25 | 2018-03-06 | Esbatech, An Alcon Biomedical Research Unit Llc | Sequence based engineering and optimization of single chain antibodies |
| WO2010046876A1 (en) * | 2008-10-22 | 2010-04-29 | Universidade De Coimbra | Method for the Functional identification of SVZ-derived oligodendrocytes based on selective resuponse to thrombin and utilization thereof |
| WO2012045324A1 (en) * | 2010-10-07 | 2012-04-12 | Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh | Method for detecting a parkinson's disease and test system |
| NZ624752A (en) | 2010-10-19 | 2015-11-27 | Mayo Foundation | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
| US9150867B2 (en) | 2011-04-28 | 2015-10-06 | Mayo Foundation For Medical Education And Research | DNA aptamers for promoting remyelination |
| DK2820042T3 (da) * | 2012-02-29 | 2019-10-28 | Baxalta GmbH | Igg-stimuleret remyelinisering af perifere nerver |
| WO2013158748A1 (en) * | 2012-04-17 | 2013-10-24 | Mayo Foundation For Medical Education And Research | Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
| US11180543B2 (en) | 2014-11-07 | 2021-11-23 | Mayo Foundation For Medical Education And Research | Treatment of neonatal hypoxia including impairments or effects thereof |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3842442B1 (en) | 2016-12-22 | 2023-11-01 | Precision Pharmaceuticals, Inc. | Compositions and methods for inhibiting arginase activity |
| US12037590B2 (en) | 2018-12-06 | 2024-07-16 | Mayo Foundation For Medical Education And Research | Short DNA aptamers and methods for promoting remyelination |
| RU2736070C1 (ru) * | 2019-09-30 | 2020-11-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Тест-модель для исследования действия лекарственных препаратов, препятствующих демиелинизации, способ ее получения и применения |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| DE3167442D1 (en) | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
| US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
| US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
| US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
| US4451570A (en) | 1981-03-26 | 1984-05-29 | The Regents Of The University Of California | Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line |
| US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
| US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| KR100372934B1 (ko) | 1990-09-25 | 2003-12-24 | 캔탑 파마슈티칼스 리서취 리미티드 | 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신 |
| JPH08507784A (ja) | 1993-03-19 | 1996-08-20 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウイルス・ワクチン |
| JPH09501055A (ja) | 1993-07-30 | 1997-02-04 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 初代リンパ球への効率的遺伝子転移 |
| EP0753069A1 (en) | 1994-04-15 | 1997-01-15 | Targeted Genetics Corporation | Gene delivery fusion proteins |
| US5591629A (en) * | 1994-04-29 | 1997-01-07 | Mayo Foundation For Medical Education & Research | Monoclonal antibodies which promote central nervous system remyelination |
-
2000
- 2000-05-30 ES ES10180642.0T patent/ES2609494T3/es not_active Expired - Lifetime
- 2000-05-30 JP JP2001582396A patent/JP5670608B2/ja not_active Expired - Lifetime
- 2000-05-30 AU AU2000261978A patent/AU2000261978B2/en not_active Expired
- 2000-05-30 CA CA2901451A patent/CA2901451C/en not_active Expired - Lifetime
- 2000-05-30 BR BR0015875-5A patent/BR0015875A/pt not_active IP Right Cessation
- 2000-05-30 IL IL15273800A patent/IL152738A0/xx unknown
- 2000-05-30 AT AT00948498T patent/ATE536375T1/de active
- 2000-05-30 EP EP00948498A patent/EP1294770B1/en not_active Expired - Lifetime
- 2000-05-30 EP EP10180642.0A patent/EP2287191B1/en not_active Expired - Lifetime
- 2000-05-30 MX MX2011013991A patent/MX347175B/es unknown
- 2000-05-30 ES ES00948498T patent/ES2376725T3/es not_active Expired - Lifetime
- 2000-05-30 EP EP10180618.0A patent/EP2287190B1/en not_active Expired - Lifetime
- 2000-05-30 CA CA2409515A patent/CA2409515C/en not_active Expired - Lifetime
- 2000-05-30 WO PCT/US2000/014902 patent/WO2001085797A1/en not_active Ceased
- 2000-05-30 MX MXPA02011163A patent/MXPA02011163A/es active IP Right Grant
- 2000-05-30 ES ES10180618.0T patent/ES2531552T3/es not_active Expired - Lifetime
- 2000-05-30 AU AU6197800A patent/AU6197800A/xx active Pending
-
2002
- 2002-11-10 IL IL152738A patent/IL152738A/en not_active IP Right Cessation
-
2011
- 2011-05-04 IL IL212686A patent/IL212686A/en not_active IP Right Cessation
-
2012
- 2012-07-30 JP JP2012168953A patent/JP5795753B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02011163A (es) | 2004-08-19 |
| EP1294770A1 (en) | 2003-03-26 |
| EP2287190B1 (en) | 2014-12-17 |
| JP2013059318A (ja) | 2013-04-04 |
| IL152738A0 (en) | 2003-06-24 |
| CA2901451A1 (en) | 2001-11-15 |
| EP2287190A3 (en) | 2011-03-23 |
| EP2287191B1 (en) | 2016-10-12 |
| ES2609494T3 (es) | 2017-04-20 |
| JP2004516807A (ja) | 2004-06-10 |
| CA2409515A1 (en) | 2001-11-15 |
| CA2409515C (en) | 2015-11-24 |
| AU2000261978B2 (en) | 2006-07-06 |
| EP2287190A2 (en) | 2011-02-23 |
| IL152738A (en) | 2011-06-30 |
| CA2901451C (en) | 2020-04-07 |
| ES2376725T3 (es) | 2012-03-16 |
| EP2287191A3 (en) | 2011-03-30 |
| ES2531552T3 (es) | 2015-03-17 |
| WO2001085797A1 (en) | 2001-11-15 |
| AU6197800A (en) | 2001-11-20 |
| ATE536375T1 (de) | 2011-12-15 |
| EP2287191A2 (en) | 2011-02-23 |
| JP5670608B2 (ja) | 2015-02-18 |
| HK1154604A1 (en) | 2012-04-27 |
| BR0015875A (pt) | 2003-06-24 |
| JP5795753B2 (ja) | 2015-10-14 |
| EP1294770B1 (en) | 2011-12-07 |
| IL212686A0 (en) | 2011-07-31 |
| IL212686A (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347175B (es) | Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central. | |
| JP7539434B2 (ja) | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 | |
| KR100483494B1 (ko) | 감마 인터페론에 대한 인간화 항체 | |
| Losman et al. | Monoclonal autoantibodies to subnucleosomes from a MRL/Mp (-)+/+ mouse. Oligoclonality of the antibody response and recognition of a determinant composed of histones H2A, H2B, and DNA | |
| JP4482054B2 (ja) | 細胞内の物質移送のための抗体から誘導されたベクター | |
| RU2207878C2 (ru) | "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование | |
| JP6591964B2 (ja) | Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 | |
| JP2024038040A5 (es) | ||
| RU2000124084A (ru) | Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты) | |
| Tian et al. | Three TNFR-binding domains of PGRN act independently in inhibition of TNFα binding and activity | |
| JP5758073B2 (ja) | 炎症性疾患の処置のためのｃｘｃｌ１３アンタゴニストおよびその使用 | |
| CN102906111B (zh) | 特异性结合乙型肝炎病毒表面抗原的人抗体 | |
| EA200901129A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| JP2006508689A (ja) | 選択的ＩＦＮ−γ経路インヒビターとしてのヒト抗ＩＦＮ−γ中和抗体 | |
| KR20230096959A (ko) | Il-10을 포함하는 이중 시토카인 융합 단백질 | |
| JP2009524428A5 (es) | ||
| WO2023009028A1 (ru) | Однодоменное антитело и его модификации, специфически связывающиеся с rbd s белка вируса sars-cov-2 | |
| JPH09500358A (ja) | 免疫感染性クラスター・ウイルス感染のための治療的戦略 | |
| DK0937153T3 (da) | Humane monoklonale antistoffer, der er specifikke for hepatitis C-virus (HCV) E2 antigen | |
| ES2358118T3 (es) | Procedimiento para la obtención de anticuerpos humanos que neutralizan la actividad biológica de una citoquina humana. | |
| WO2019034883A1 (en) | Therapy and diagnostics | |
| WO1996021020A3 (en) | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases | |
| CN114174516A (zh) | 制备抗原结合单元的方法 | |
| EP0667781A4 (en) | PEPTIDE AS A DIAGNOSIS AND THERAPY AGENT FOR SPONDYLOARTHROPATHIA. | |
| WO2004110355A3 (en) | Compositions and methods including a recombinant human mab that promotes cns remyelination |